Trials / Completed
CompletedNCT01590199
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study"
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001 | |
| DRUG | SOM230 |
Timeline
- Start date
- 2012-05-18
- Primary completion
- 2018-09-11
- Completion
- 2018-09-11
- First posted
- 2012-05-02
- Last updated
- 2019-04-16
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01590199. Inclusion in this directory is not an endorsement.